Abstract
Galanin receptor 1 (GALR1) maps to a common region of 18q loss in head and neck squamous cell carcinomas and is frequently inactivated by methylation. To investigate effects of GALR1 and its signaling pathways, we stably expressed hemaglutinin-tagged GALR1 in a human oral carcinoma cell line (UM-SCC-1-GALR1) that expresses no endogenous GALR1. In transfected cells, galanin induced activation of the extracellular-regulated protein kinase-1/2 (ERK1/2) and suppressed proliferation. Galanin stimulation mediated decreased expression of cyclin D1 and increased expression of the cyclin-dependent kinase inhibitors (CKI), p27Kip1 and p57Kip2. Pretreatment with the ERK1/2-specific inhibitor U0126 prevented these galanin-induced effects. Phosphatidylinositol 3-kinase (PI3K) pathway activation did not differ in UM-SCC-1-GALR1 and UM-SCC-1-mock cells after galanin treatment. Pertussis toxin and LY294002 inhibition demonstrated that galanin and GALR1 induce ERK1/2 activation via Gαi, not the PI3K pathway-linked to the Gβγ subunit. Galanin and GALR1 also inhibit colony formation and tumor growth in vivo. Our results implicate GALR1, a Gi protein-coupled receptor, as a tumor suppressor gene that inhibits cell proliferation via ERK1/2 activation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akervall J, Bockmuhl U, Petersen I, Yang K, Carey TE, Kurnit DM . (2003). The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res 9: 1750–1755.
Berger A, Lang R, Moritz K, Santic R, Hermann A, Sperl W et al. (2004). Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. Endocrinology 145: 500–507.
Branchek TA, Smith KE, Gerald C, Walker MW . (2000). Galanin receptor subtypes. Trends Pharmacol Sci 21: 109–117.
Cody JD, Hale DE, Brkanac Z, Kaye CI, Leach RJ . (1997). Growth hormone insufficiency associated with haploinsufficiency at 18q23. Am J Med Genet 71: 420–425.
Dixon BS, Evanoff D, Fang WB, Dennis MJ . (2002). Bradykinin B1 receptor blocks PDGF-induced mitogenesis by prolonging ERK activation and increasing p27Kip1. Am J Physiol Cell Physiol 283: C193–C203.
Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG et al. (1997). Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381–3385.
Facchinetti MM, De Siervi A, Toskos D, Senderowicz AM . (2004). UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway. Cancer Res 64: 3629–3637.
Ferbeyre G, de Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GJ et al. (2002). Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 22: 3497–3508.
Gendron L, Oligny JF, Payet MD, Gallo-Payet N . (2003). Cyclic AMP-independent involvement of Rap1/B-Raf in the angiotensin II AT2 receptor signaling pathway in NG108-15 cells. J Biol Chem 278: 3606–3614.
Han J, Tsukada Y, Hara E, Kitamura N, Tanaka T . (2005). Hepatocyte growth factor induces redistribution of p21(CIP1) and p27(KIP1) through ERK-dependent p16(INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells. J Biol Chem 280: 31548–31556.
Henson BS, Neubig RR, Jang I, Ogawa T, Zhang Z, Carey TE et al. (2005). Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biol Chem 280: 22564–22571.
Hoffmann MJ, Florl AR, Seifert HH, Schulz WA . (2005). Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 114: 406–413.
Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML . (2000). Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 60: 249–252.
Kranenburg O, Moolenaar WH . (2001). Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene 20: 1540–1546.
Lahlou H, Saint-Laurent N, Esteve JP, Eychene A, Pradayrol L, Pyronnet S et al. (2003). sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 278: 39356–39371.
Lu X, Lundstrom L, Bartfai T . (2005). Galanin (2–11) binds to GalR3 in transfected cell lines: limitations for pharmacological definition of receptor subtypes. Neuropeptides 39: 165–167.
Massarelli E, Brown E, Tran NK, Liu DD, Izzo JG, Lee JJ et al. (2005). Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer 103: 952–959.
Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K et al. (2002). Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 62: 3819–3825.
Misawa K, Ueda Y, Kanazawa T, Misawa Y, Takebayashi S, Mineta H et al. (2004). CpG hypermethylation of the promoter region and inactivation of GALR1 in head and neck cancer. Proc Am Assoc Cancer Res 44: 4271.
Mochizuki N, Ohba Y, Kiyokawa E, Kurata T, Murakami T, Ozaki T et al. (1999). Activation of the ERK/MAPK pathway by an isoform of rap1GAP associated with G alpha(i). Nature 400: 891–894.
Otis M, Campbell S, Payet MD, Gallo-Payet N . (2005). Angiotensin II stimulates protein synthesis and inhibits proliferation in primary cultures of rat adrenal glomerulosa cells. Endocrinology 146: 633–642.
Pearlstein RP, Benninger MS, Carey TE, Zarbo RJ, Torres FX, Rybicki BA et al. (1998). Loss of 18q predicts poor survival of patients with squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer 21: 333–339.
Pumiglia KM, Decker SJ . (1997). Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 94: 448–452.
Seufferlein T, Rozengurt E . (1996). Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res 56: 5758–5764.
Takebayashi S, Hickson A, Ogawa T, Jung KY, Mineta H, Ueda Y et al. (2004). Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer. Genes Chromosomes Cancer 41: 145–154.
Takebayashi S, Ogawa T, Jung KY, Muallem A, Mineta H, Fisher SG et al. (2000). Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. Cancer Res 60: 3397–3403.
Tatemoto K, Rokaeus A, Jornvall H, McDonald TJ, Mutt V . (1983). Galanin – a novel biologically active peptide from porcine intestine. FEBS Lett 164: 124–128.
Tsukada Y, Miyazawa K, Kitamura N . (2001). High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2. J Biol Chem 276: 40968–40976.
Wang S, Hashemi T, Fried S, Clemmons AL, Hawes BE . (1998). Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 37: 6711–6717.
Wittau N, Grosse R, Kalkbrenner F, Gohla A, Schultz G, Gudermann T . (2000). The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins. Oncogene 19: 4199–4209.
Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M . (1997). Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17: 5598–5611.
Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, Hoey T et al. (2005). G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the beta-catenin pathway. Proc Natl Acad Sci USA 102: 6027–6032.
Acknowledgements
This work was supported by National Institutes of Health grants R01 DE12477, University of Michigan Head and Neck SPORE Grant P50 CA97248, University of Michigan's Cancer Center Support Grant P30 CA46592, a Research Resources Core grant NIH NIDCD P30 DC05188, and a Grant-in-Aid for Scientific Research (No. 452662) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kanazawa, T., Iwashita, T., Kommareddi, P. et al. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene 26, 5762–5771 (2007). https://doi.org/10.1038/sj.onc.1210384
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210384
Keywords
This article is cited by
-
Screening potential immune signatures for early-stage basal-like/triple-negative breast cancer
World Journal of Surgical Oncology (2022)
-
Promoter hypermethylation of GALR1 acts as an early epigenetic susceptibility event in colorectal carcinogenesis
Journal of Human Genetics (2022)
-
Activation of Galanin Receptor 1 with M617 Attenuates Neuronal Apoptosis via ERK/GSK-3β/TIP60 Pathway After Subarachnoid Hemorrhage in Rats
Neurotherapeutics (2021)
-
Epigenetic silencing of SALL3 is an independent predictor of poor survival in head and neck cancer
Clinical Epigenetics (2017)
-
Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer
Clinical & Experimental Metastasis (2016)